

Quantification of functional GIP using *iLite*[®] GIP Assay Ready Cells

For research and professional use only. Not for use in diagnostic procedures.

*This application note contains a suggested protocol and performance data.
Each individual laboratory must set up their own method and perform relevant validations.*

Background

Glucose-dependent insulintropic polypeptide (GIP) is an incretin hormone belonging to the secretin/vasoactive intestinal polypeptide family of gastrointestinal regulatory peptides (1,2). GIP and another incretin hormone, glucagon-like peptide-1 (GLP-1), are the primary physiological peptides responsible for regulating postprandial metabolism in humans, accounting for approximately 60-80% of the insulin secretion after a meal (1,3). GIP initiates metabolic events through the amplification of glucose-dependent insulin secretion following ingestion of lipids, carbohydrates, or amino acids. Postprandial nutrient disposition is primarily mediated by insulin and glucagon, including the storage of excess nutrients in adipose tissue (1-4).

GIP is a 42-amino acid polypeptide produced by enteroendocrine K cells of the proximal small intestine (1). It binds to its specific receptor, the glucose-dependent insulintropic polypeptide receptor (GIPR), expressed in the pancreas, stomach, small intestine, adipose tissue, the heart, distinct neuronal populations, bone, specific immune cell populations, and endothelial cells (2,4). Current incretin-based therapies comprise GLP-1 receptor agonists (e.g., semaglutide) and newer dual GIP/GLP-1 receptor co-agonists (e.g., tirzepatide), which leverage complementary hormonal pathways to treat hyperglycaemia in people with type 2 diabetes and promote body weight reduction. (5,6). Dual agonists represent an evolution of GLP-1 therapies, combining GIP and GLP-1 receptor activation to achieve greater metabolic efficacy and form the basis of emerging next-generation anti-obesity pharmacotherapies (5,7).

The *iLite*[®] GIP Assay Ready Cells can be used for functional studies of GIP, the receptor GIPR and their interaction.

Principle of the assay

The *iLite*[®] GIP Assay Ready Cells are engineered cells, optimized to be responsive to GIP receptor agonists, resulting in a proportional expression of Firefly Luciferase (FL). Binding of GIP to its receptor results in activation of the CRE regulated Firefly luciferase reporter gene construct. *iLite*[®] GIP Assay Ready Cells also contain the Renilla Luciferase (RL) reporter gene, under the control of a constitutive promoter. The constitutive expression of RL allows normalization of GIP induced FL activity, and renders assay results independent of variations in cell number or serum matrix effects. The luciferase signal can be measured in a luminometer following addition and incubation of luciferase substrate. The Firefly luciferase signal is proportional to the concentration of functional GIP in a sample (Fig.1).

Specimen collection

The *iLite*[®] GIP Assay Ready Cells can be used for measuring concentration of GIP receptor agonists in test samples including human serum.

Material and equipment needed

Material and equipment	Suggested supplier	Reference
<i>iLite</i> [®] GIP Assay Ready Cells	Svar Life Science	BM4110
Diluent (DMEM containing 9% heat inactivated FBS + 1% Penicillin-Streptomycin)	Gibco	31966-021 (DMEM) 26140-079 (FBS) 15140-122 (Penicillin-Streptomycin)
Tirzepatide or other GIP receptor agonists	Eli Lilly	NA
Firefly/Renilla luciferase substrate	Promega	E2920, Dual-Glo Luciferase Assay System
Plate; White walled micro well plate suitable for luminescence	Revvity	6055680
Microplate Luminometer with appropriate reading software – no filter on luminometer	Contact Svar Life Science for list of recommended suppliers	NA
Incubator, 37 °C with 5% CO ₂	NA	NA
Water bath, 37 °C	NA	NA
Single-channel and multi-channel pipettes with polypropylene disposable tips	NA	NA
Polypropylene tubes or plate for dilution	NA	NA
Single-use polypropylene reservoir	NA	NA
Plate shaker	NA	NA
Timer	NA	NA

Protocol

Preparation of calibrators (GIP receptor agonist)

The peptide Tirzepatide from Eli Lilly has been used to stimulate the *iLite*[®] GIP Assay Ready Cells. The table below shows the dilutions of Tirzepatide, used for QC release of the *iLite*[®] GIP Assay Ready Cells.




Figure 1. Example of Tirzepatide calibration curve.

Calibrator	Tirzepatide
	Suggested calibrator solution conc. (pM)
A	150
B	75
C	38
D	22
E	11
F	5.5
G	0.92
H	0

Table 1. Suggested calibrator solution concentrations for Tirzepatide.

Assay preparation and incubation

1. Design a plate layout. It is recommended to perform the test at least in duplicates.
2. Dilute calibrators, controls, and samples to fall within the expected in assay values of 0 - 75 pM.
3. Add 40 µL calibrators, controls, and samples in duplicate to assigned wells (final concentration will be half of solution concentration).

4. Thaw the vial of *iLite*[®] GIP Assay Ready Cells in a 37°C water bath with gentle agitation. The cell suspension is mixed very carefully ten times with pipette to ensure a homogeneous distribution of cells.
5. Dilute 250 µL cell suspension with 5.75 mL Diluent.
6. Add 40 µL diluted cells to each well.
7. Place the lid on the plate, mix and incubate for 5 hours at 37 °C with 5% CO₂.

Adding substrate solutions

8. Equilibrate the plate and the substrate solution to room temperature.
9. Prepare the **Firefly luciferase** substrate according to the supplier's instructions and add 80 µL per well. Mix and protect the plate from light. After 10 minutes incubation at room temperature read in a luminometer.
10. If appropriate, prepare the **Renilla luciferase** substrate according to the supplier's instructions and add 80 µL per well. Mix and protect the plate from light. After 10 minutes incubation at room temperature read in a luminometer.

Precautions


- This application note is intended for professional laboratory research use only. The data and results originating from following the Application Note should not be used either in diagnostic procedures or in human therapeutic applications.
- Use and handle the material and instruments referenced according to the supplier's/manufacturer's instructions or product specifications accompanying the individual material and instruments.
- Dispose of all sample specimens, infected or potentially infected material in accordance with good microbiological practice. All such materials should be handled and disposed as potentially infectious.
- Residues of chemicals and preparations are generally considered as biohazardous waste and should be inactivated prior to disposal by autoclaving or using bleach. All such materials should be disposed in accordance with established safety procedures.

Proprietary Information

In accepting delivery of *iLite*[®] Assay Ready Cells the recipient agrees not to sub-culture these cells, attempt to sub-culture them or to give them to a third-party recipient, and only to use them directly in assays. *iLite*[®] cell-based products are covered by patents which are the property of Svar Life Science AB and any attempt to reproduce the delivered *iLite*[®] Assay Ready Cells is an infringement of these patents.

QUICK GUIDE

Quantification of functional GIP using *iLite*[®] GIP Assay Ready Cells



Troubleshooting and FAQ

Please consult the Svar Life Science website www.svarlifescience.com

References

1. M Michael Wolfe, Michael O Boylan, William W Chin, Glucose-Dependent Insulinotropic Polypeptide in Incretin Physiology: Role in Health and Disease, *Endocrine Reviews*, Volume 46, Issue 4, August 2025, Pages 479–500.
2. Müller T, D'Alessio D, Campbell J, Glucose-dependent insulinotropic polypeptide (GIP), *Trends in Endocrinology & Metabolism*, 2026; 37, 180-181.
3. Holst JJ, Rosenkilde MM. GIP as a Therapeutic Target in Diabetes and Obesity: Insight From Incretin Co-agonists. *J Clin Endocrinol Metab*. 2020 Aug 1;105(8): e2710–6.
4. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. *Gastroenterology*. 2007 May;132(6):2131-57.
5. Melson E, Ashraf U, Papamargaritis D, Davies MJ. What is the pipeline for future medications for obesity? *Int J Obes (Lond)*. 2025 Mar;49(3):433-451.
6. Nauck MA, Tuttle KR, Tschöp MH, Blüher M. Glucagon-like receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits. *Lancet*. 2026 Feb 28;407(10531):892-908.
7. Ciardullo S, Morieri ML, Daniele G, Fiorentino TV, Mezza T, Tricò D, Consoli A, Del Prato S, Giorgino F, Piro S, Solini A, Avogaro A. GLP1-GIP receptor co-agonists: a promising evolution in the treatment of type 2 diabetes. *Acta Diabetol*. 2024 Aug;61(8):941-950.